News

Grenova Appoints New Chief Executive Officer to Lead Next Phase of Growth Across Global Automation Platform

Grenova today announced the appointment of Ted Hull as Chief Executive Officer. Hull will lead Grenova and its automation divisions, Peak Robotics and Peak Analysis & Automation (PAA), guiding the organization through its next phase of growth as a global platform delivering automation-ready solutions to laboratories world-wide.

Grenova and its division partners are backed by healthcare-focused private equity firm Peloton Equity.

Hull brings more than 30 years of leadership experience in the life sciences and diagnostics industries and has served on the Grenova Board of Directors for the past 13 months. He previously served as CEO of Bako Diagnostics and Genova Diagnostics – a former FFC company, Peloton’s predecessor firm – and has worked closely with Peloton Equity as an operating partner.

“Given the increasing demand for automation across laboratory workflows, this is a particularly exciting time to build a scaled, integrated platform in this space. Grenova, Peak Robotics, and PAA each bring world-class capabilities in their respective fields, creating a unique set of solutions for our customers,” said Ted Hull. “I’m incredibly excited to work alongside this team to shape the future of scientific automation.”

“We’re thrilled to partner with Ted again,” said Michael O’Rourke, Partner at Peloton Equity. “Ted brings a rare combination of operational leadership, industry expertise, and a deep understanding of how to scale growth companies. Having worked closely with the company and served alongside the leadership team, he is uniquely positioned to lead this next phase of growth.”

With the combined capabilities of Grenova’s technologies and the automation and integration expertise of Peak Robotics and PAA, the organization is positioned to deliver modular, scalable solutions and become a global leader in laboratory automation.

Read more here.

Recent News

11/17/2026

LifeNet Health Announced that Rony Thomas has Resigned

LifeNet Health announced that Rony Thomas has resigned as President and Chief Executive Officer and as a member of its Board of Directors, effective November 13, 2026. Mr. Thomas led LifeNet Health since 2004. During his tenure, the organization grew into a global leader in organ and tissue procurement and regenerative medicine. “On behalf of …

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …

11/04/2026

$6 Million in Philanthropic Gifts Establishes UVA Biotech Innovation Fund

The University of Virginia Paul and Diane Manning Institute of Biotechnology received gifts totaling $6 million from philanthropists to establish the UVA Biotech Innovation Fund. This fund will provide long-term support for the UVA SPARK Innovative Medicines program, helping accelerate promising discoveries toward new treatments and cures. “The mission of the UVA Manning Institute of …